TLT.VStockTheralase Technologies Inc.
Verdicts genuinely change. Free email alert the moment TLT.V's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown business activity not assessed▾
AAOIFI ● FAIL ▾
Usmani ● FAIL ▾
Dow Jones ● REVIEW ▾
S&P Shariah ● REVIEW ▾
MSCI ● FAIL ▾
MSCI M ● REVIEW ▾
FTSE ● FAIL ▾
Business activity could not be assessed — classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
ℹ️ Ratios above can still show Pass — business-activity screening itself couldn't run, and it's a hard gate a ratio pass can't substitute for.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Theralase Technologies Inc. (TLT.V) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-09-16). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
449 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.
Business activity: could not be assessed
classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
Combined verdict: AAOIFI Non Compliant Usmani Non Compliant Dow Jones Islamic Needs Review S&P Shariah Needs Review MSCI Islamic Non Compliant MSCI Islamic M Needs Review FTSE Shariah Non Compliant
ℹ️ AAOIFI, Usmani, MSCI Islamic, FTSE Shariah screen this company as Non-Compliant on the financial ratios alone — a ratio failure is decisive on its own, so those verdicts stand regardless of what the business-activity screen concluded. The business-activity screen is a second, independent hard gate, and it did not reach a conclusion here.
The three ratios
Computed from the company's own filing, measured against market cap — the AAOIFI basis. Other standards move both the line and the denominator, which is what the breakdown above shows.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from TLT.V's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $596.3K | 2025-12-31 | — |
| Interest-bearing debtShort and long-term borrowings | $334.5K | 2025-12-31 | — |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $133.6K | 2025-12-31 | — |
| Total assetsBalance sheet total | $2.6M | 2025-12-31 | — |
| Market capDenominator for AAOIFI | $40.1M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | not measured | — | — |
| 24-month average market capDenominator for Dow Jones Islamic Market | not measured | — | — |
| Non-permissible revenueInterest and excluded income | $57.9K | 2025-12-31 | — |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
What changed, and when
Verdict history for TLT.V. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for TLT.V has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
ℹ️ no compliance scan has run for 5 days - this is not a reading of today
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 65.50 | NEUTRAL |
| Stochastic %K (14) | 42.86 | NEUTRAL |
| CCI (20) | 310.54 | SELL |
| Williams %R (14) | -57.14 | NEUTRAL |
| MACD (12,26,9) | 0.00 | BUY |
| ROC (10) | 16.67 | BUY |
| Momentum (10) | 0.03 | BUY |
| EMA (10) | 0.20 | BUY |
| SMA (10) | 0.19 | BUY |
| EMA (20) | 0.19 | BUY |
| SMA (20) | 0.19 | BUY |
| EMA (30) | 0.19 | BUY |
| SMA (30) | 0.19 | BUY |
| EMA (50) | 0.20 | BUY |
| SMA (50) | 0.19 | BUY |
| EMA (100) | 0.21 | SELL |
| SMA (100) | 0.22 | SELL |
| EMA (200) | 0.22 | SELL |
| SMA (200) | 0.25 | SELL |
About Theralase Technologies Inc.
Healthcare · Medical Devices
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Background via Yahoo Finance — informational, not part of the verdict.
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-20 · Asset managers net 901377 (-14458)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.